Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Cash from Operations (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Cash from Operations data on record, last reported at 13893000.0 in Q3 2025.

  • For Q3 2025, Cash from Operations fell 68.75% year-over-year to 13893000.0; the TTM value through Sep 2025 reached 50180000.0, up 6.72%, while the annual FY2024 figure was 57017000.0, 6.3% down from the prior year.
  • Cash from Operations reached 13893000.0 in Q3 2025 per NWBO's latest filing, down from 6688000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 6688000.0 in Q2 2025 and bottomed at 20181000.0 in Q4 2024.
  • Average Cash from Operations over 5 years is 12196157.89, with a median of 12406000.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: plummeted 129.83% in 2022, then skyrocketed 58.71% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 11246000.0 in 2021, then grew by 21.31% to 8849000.0 in 2022, then crashed by 91.64% to 16958000.0 in 2023, then dropped by 19.01% to 20181000.0 in 2024, then soared by 31.16% to 13893000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 13893000.0 in Q3 2025, 6688000.0 in Q2 2025, and 9418000.0 in Q1 2025.